FNYS
CADX

First New York Securities’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

First New York Securities’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-2
Closed – – 542
2013
Q4 		$0 Hold
2
– – ﹤0.01% 481
2013
Q3 		$0 Buy
+2
New +$13 ﹤0.01% 549

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

First New York Securities's CADX Position: Q1 2014 in Review

First New York Securities sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 2 shares.

First New York Securities first reported a position in CADX in Q3 2013 and held it in 2 quarters. The position peaked at $0 in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • First New York Securities reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • First New York Securities sold 2 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014.
  • First New York Securities first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q3 2013 and held it in 2 quarters.
  • First New York Securities's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $0 in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on First New York Securities's 13F filing for Q1 2014, filed 15 May 2014.